Psoriatic Arthritis Treatment Market To Reach $19.91 Billion By 2030

Psoriatic Arthritis Treatment Market Growth & Trends

The global psoriatic arthritis treatment market size is expected to reach USD 19.91 billion by 2030, registering a CAGR of 9.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Emergence of biosimilars, new product launches, and a rising consumer awareness are some of the key factors driving the growth.

Biologics generated the highest revenue among other drug classes, in 2018. The segment growth is driven by the demand for targeted therapy, improved safety & efficacy profiles, anticipated launches of several promising pipeline candidates, and strong commercial performances of existing products. DMARDs is also expected to maintain a steady growth rate, supported by the first-line action of corticosteroids as well as the impending launch of JAK-inhibitors and TYK2 kinase inhibitors.

North America captured the highest market share in 2018, propelled by high healthcare expenditure, disease prevalence, regional presence of key manufacturers, and rapid rise in consumer awareness. Asia Pacific is expeted to demonstrate the fastest regional growth over the forecast period, driven by a rising trend of biosimilars, improvement in healthcare infrastructure, and increasing disposable income.

Some key players in the psoriatic arthritis (PsA) treatmentmarket include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer, Inc.; and UCB S.A.

 Request a free sample copy or view report summary: Psoriatic Arthritis Treatment Market Report

Psoriatic Arthritis Treatment Market Report Highlights

• Biologics dominated the psoriatic arthritis industry and accounted for a revenue share of 49.1% in 2024 and is expected to grow at the fastest CAGR over the forecast period.

• Prescriptions dominated the market, accounting for a revenue share of 81.1% in 2024, and are expected to grow at the fastest CAGR over the forecast period.

• Injectables dominated the market and accounted for a revenue share of 51.1% in 2024. The oral segment is expected to grow significantly over the forecast period.

• North America psoriatic arthritis treatment dominated the global market and accounted for a revenue share of 38.7% in 2024.The U.S. psoriatic arthritis treatment industry is expected to grow significantly over the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 10.9% over the forecast period.

Psoriatic Arthritis Treatment Market Segmentation

Grand View Research has segmented global psoriatic arthritis market report based on drug class, type, route of administration, and region:

Psoriatic Arthritis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• NSAIDs

• DMARD

• Biologics

• Others

Psoriatic Arthritis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Prescriptions

• OTC

Psoriatic Arthritis Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Topical

• Oral

• Injectable

Psoriatic Arthritis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2026)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • Spain

  • France

  • Italy

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

Key Players of Psoriatic Arthritis Treatment Market

• AbbVie Inc.

• Amgen Inc.

• Johnson & Johnson Services, Inc.

• Bristol-Myers Squibb Company

• Novartis AG

• Eli Lilly and Company

• Pfizer, Inc.